|
SE454715B
(sv)
|
1986-09-29 |
1988-05-24 |
Gkn Stenman Ab |
Tryckeselement
|
|
JPH0517595A
(ja)
|
1991-07-15 |
1993-01-26 |
Matsushita Electric Ind Co Ltd |
高分子超薄膜エレクトレツト及びその製造方法
|
|
EP1286700A2
(en)
|
2000-06-01 |
2003-03-05 |
Universite Catholique De Louvain |
Tumor activated prodrug compounds
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
JP4334866B2
(ja)
|
2000-10-09 |
2009-09-30 |
アイシス イノヴェイション リミテッド |
治療用抗体
|
|
US20040109855A1
(en)
|
2002-07-23 |
2004-06-10 |
Herman Waldmann |
Therapeutic antibodies with reduced side effect
|
|
WO2004021861A2
(en)
|
2002-09-03 |
2004-03-18 |
Vit Lauermann |
Targeted release
|
|
US7427659B2
(en)
|
2003-10-24 |
2008-09-23 |
Amgen Inc. |
Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction
|
|
US7541330B2
(en)
*
|
2004-06-15 |
2009-06-02 |
Kosan Biosciences Incorporated |
Conjugates with reduced adverse systemic effects
|
|
CA2578131A1
(en)
*
|
2004-09-10 |
2006-03-23 |
Wyeth |
Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
|
|
EP1805320B1
(en)
|
2004-10-22 |
2014-09-03 |
Amgen Inc. |
Methods for refolding of recombinant antibodies
|
|
CN1930186A
(zh)
|
2005-03-03 |
2007-03-14 |
阿勒根公司 |
为获得梭菌毒素的梭菌细菌培养基及方法
|
|
WO2006122424A1
(en)
*
|
2005-05-19 |
2006-11-23 |
Caprion Pharmaceuticals Inc. |
Protein depletion using volatile binding buffers
|
|
WO2007027935A2
(en)
|
2005-08-31 |
2007-03-08 |
The Regents Of The University Of California |
Cellular libraries of peptide sequences (clips) and methods of using the same
|
|
EP1993608A1
(en)
|
2006-03-10 |
2008-11-26 |
Diatos |
Anticancer drugs conjugated to antibody via an enzyme cleavable linker
|
|
CN102391358B
(zh)
|
2006-04-05 |
2016-08-10 |
艾伯维生物技术有限公司 |
抗体纯化
|
|
US8293685B2
(en)
|
2007-07-26 |
2012-10-23 |
The Regents Of The University Of California |
Methods for enhancing bacterial cell display of proteins and peptides
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
BR112013002167A2
(pt)
|
2010-08-24 |
2016-05-31 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
PE20150605A1
(es)
|
2012-04-27 |
2015-05-28 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
|
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
|
SG11201408554QA
(en)
|
2012-06-22 |
2015-02-27 |
Cytomx Therapeutics Inc |
Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
|
|
WO2013192546A1
(en)
|
2012-06-22 |
2013-12-27 |
Cytomx Therapeutics, Inc. |
Activatable antibodies having non-binding steric moieties and mehtods of using the same
|
|
EP2882844B1
(en)
|
2012-08-10 |
2018-10-03 |
Cytomx Therapeutics Inc. |
Protease-resistant systems for polypeptide display and methods of making and using thereof
|
|
US9487590B2
(en)
|
2012-09-25 |
2016-11-08 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
|
|
EP2934603A1
(en)
|
2012-12-20 |
2015-10-28 |
Omrix Biopharmaceuticals Ltd. |
Viral inactivated biological mixture
|
|
JP6605957B2
(ja)
|
2013-01-04 |
2019-11-13 |
シトムクス セラピューティクス，インコーポレイティド |
生体系におけるプロテアーゼ活性を検出するための組成物及び方法
|
|
WO2014209508A1
(en)
*
|
2013-05-13 |
2014-12-31 |
Medimmune, Llc |
Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
|
|
BR112015030514A2
(pt)
|
2013-06-04 |
2017-08-29 |
Cytomx Therapeutics Inc |
Composições e métodos para conjugação de anticorpos ativáveis
|
|
JP6693872B2
(ja)
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス，インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
KR20250051130A
(ko)
|
2013-09-25 |
2025-04-16 |
싸이톰스 테라퓨틱스, 인크. |
매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
EP3628328B1
(en)
|
2014-01-31 |
2022-09-14 |
Cytomx Therapeutics Inc. |
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
EP3197916A2
(en)
|
2014-09-25 |
2017-08-02 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
|
IL300408B2
(en)
|
2015-01-20 |
2025-11-01 |
Cytomx Therapeutics Inc |
Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
|
|
HRP20192217T1
(hr)
*
|
2015-03-06 |
2020-02-21 |
F. Hoffmann - La Roche Ag |
ULTRA-PROČIŠĆENI DsbA I DsbC TE POSTUPCI NJIHOVE IZRADE I UPORABE
|
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
EP3778640A1
(en)
|
2015-05-01 |
2021-02-17 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
|
AU2016258988A1
(en)
|
2015-05-04 |
2017-12-07 |
Cytomx Therapeutics, Inc |
Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof
|
|
TWI787796B
(zh)
|
2015-05-04 |
2022-12-21 |
美商Ｃｙｔｏｍｘ生物製藥公司 |
抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法
|
|
BR112017023872A2
(pt)
|
2015-05-04 |
2018-07-24 |
Cytomx Therapeutics Inc |
anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos
|
|
JP6841754B2
(ja)
|
2015-05-13 |
2021-03-10 |
中外製薬株式会社 |
多重抗原結合分子融合体、医薬組成物、線状エピトープの同定方法、および多重抗原結合分子融合体の製造方法
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
WO2017025698A1
(en)
|
2015-08-11 |
2017-02-16 |
Queen Mary University Of London |
Bispecific, cleavable antibodies
|
|
CN108697798A
(zh)
|
2016-02-16 |
2018-10-23 |
达纳-法伯癌症研究所有限公司 |
免疫疗法组合物及方法
|
|
AU2017229687A1
(en)
|
2016-03-08 |
2018-09-20 |
Takeda Pharmaceutical Company Limited |
Inducible binding proteins and methods of use
|
|
WO2017162587A1
(en)
|
2016-03-22 |
2017-09-28 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific molecules
|
|
CN109562190A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗egfr抗体药物偶联物
|
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
|
RS61828B1
(sr)
|
2016-06-08 |
2021-06-30 |
Abbvie Inc |
Anti-b7-h3 antitela i antitelske konjugacije lekova
|
|
SG11201809685XA
(en)
|
2016-06-15 |
2018-11-29 |
Agency Science Tech & Res |
A method of enhancing the performance of chromatography methods for purification of proteins
|
|
JP7055538B2
(ja)
|
2016-07-14 |
2022-04-18 |
ピュリディファイ リミテッド |
ポリマーナノファイバーを含む官能化クロマトグラフィー媒体及びそれを製造する方法
|
|
US11312745B2
(en)
|
2016-07-22 |
2022-04-26 |
Amgen Inc. |
Methods of purifying Fc-containing proteins
|
|
WO2018022628A1
(en)
*
|
2016-07-25 |
2018-02-01 |
Cephalon, Inc. |
Affinity chromatography wash buffer
|
|
JP2019530646A
(ja)
|
2016-08-12 |
2019-10-24 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
タンパク質精製法
|
|
AU2017312785B2
(en)
|
2016-08-16 |
2024-10-10 |
Regeneron Pharmaceuticals, Inc. |
Methods for quantitating individual antibodies from a mixture
|
|
EP3504222A1
(en)
|
2016-08-23 |
2019-07-03 |
Alexion Pharmaceuticals, Inc. |
Method of purifying a heterologous protein from an egg white
|
|
WO2018053268A1
(en)
|
2016-09-17 |
2018-03-22 |
C Technologies |
Monitoring of compounds
|
|
CN110072890B
(zh)
|
2016-11-03 |
2022-11-29 |
百时美施贵宝公司 |
可活化的抗ctla-4抗体及其用途
|
|
JP2020530554A
(ja)
*
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
|
|
PE20210125A1
(es)
*
|
2017-10-14 |
2021-01-19 |
Abbvie Inc |
Conjugados de farmaco-anticuerpo activable anti-cd71 y metodos de uso de estos
|
|
KR20260090008A
(ko)
*
|
2017-11-01 |
2026-06-16 |
추가이 세이야쿠 가부시키가이샤 |
생물 활성이 저하된 항체 배리언트 및 아이소폼
|
|
AR113862A1
(es)
|
2017-12-01 |
2020-06-17 |
Seattle Genetics Inc |
Anticuerpos anti-cd47 y sus usos para tratar cáncer
|
|
CA3085177A1
(en)
*
|
2018-01-31 |
2019-08-08 |
Regeneron Pharamaceuticals, Inc. |
System and method for characterizing size and charge variant drug product impurities
|
|
WO2019148444A1
(en)
*
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
US20200405890A1
(en)
*
|
2018-02-21 |
2020-12-31 |
Cytomx Therapeutics, Inc. |
Positron emission tomography imaging of activatable binding polypeptides and related compositions thereof
|
|
TW202112801A
(zh)
*
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
純化遮蔽抗體之方法
|
|
CN114341189A
(zh)
*
|
2019-06-12 |
2022-04-12 |
奥美药业有限公司 |
全新il-15前药及其应用
|